Today Organon announces the launch of a clinical trial website - www.organon-trials.com - that will provide results of the company’s completed trials and a registry of ongoing trials.
June 16, 2005, Oss, The Netherlands - Today Organon announces the launch of a clinical trial website - www.organon-trials.com - that will provide results of the company's completed trials and a registry of ongoing trials. The website will further increase the transparency of the clinical trials Organon sponsors. The site is freely accessible without restriction.
"Organon is committed to provide transparency about the trials we conduct by making this information available in the public domain. We are pleased to be one of the first pharmaceutical companies to introduce such an initiative," commented Dr Henk Jan Out, Head of Global Clinical Development at Organon. With this action, Organon follows the recommendation from the joint pharmaceutical company associations and editors of the major medical journals.
The clinical trial registry contains information on all phase III and beyond trials currently taking place.1 This includes a unique identifying number, purpose of the study, study type and design, eligibility criteria, target number of patients, countries where the study is running and contact information.
The clinical trial results section will summarize the findings of the clinical trials that have been performed with currently available major products of Organon. The number will grow as additional older trials are added. In addition, once trials posted on the registry have been completed and marketing approval gained in one country, the results from all studies - including those preceding the phase III trials - will be posted in the clinical trial results section. Similarly, Organon will also report results of earlier trials when already marketed drugs have been approved in new indications.
Both the registry and results sections provide scientific, non-promotional and comprehensive summaries of clinical trials in a consistent format irrespective of whether the results may be viewed as positive or negative for the medicine concerned. The site will be updated regularly to ensure the information is accurate and up-to-date.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.